Biotechnology
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based thera...
2026-05-28 10:43
5307
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
SHANGHAI, May 28, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, the roundtable featured Dr. Bing Xia, Vice...
2026-05-28 10:37
6048
Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-05-28 08:00
5557
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test
SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions
2026-05-28 06:00
6041
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, the roundtable featured Dr. Bing Xia, Vice...
2026-05-27 20:00
6937
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII‑179 treatment achieved the most robust fun...
2026-05-27 19:00
7497
Announcement of The Shaw Laureates 2026
HONG KONG, May 27, 2026 /PRNewswire/ -- The Shaw Prize in Astronomy is awarded in equal shares to Ken'ichi Nomoto Emeritus Professor and Visiting Senior Scientist of the Kavli Institute for the Physics and Mathematics of the Universe, University of Tokyo, Japan and Stanford Woosley Professor o...
2026-05-27 17:36
4913
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
* Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) * Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults * Authorization supported by the Phase 3 SUNRISE trial conducted in a predominant...
2026-05-26 14:38
6252
sweelin® Approved in Singapore as a Food Additive expanding Amai Proteins' Regulatory Footprint into Asia
Amai Proteins has achieved a major regulatory milestone with the Singapore Food Agency (SFA) approval of sweelin®, its flagship sweet protein, for use as a sweetening agent in food and beverage products. sweelin® is a next-generation sweet protein that enables significant sugar reduction and rep...
2026-05-25 16:00
5327
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
Satellite symposium and exhibition engagement highlighted strong physician
interest in MRD, MCED, and evidence-driven adoption of genomic testing.
TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions
2026-05-22 14:45
8487
Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China
NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabl...
2026-05-22 09:50
5518
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's tropho...
2026-05-21 22:08
11166
Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings
SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company " or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final res...
2026-05-21 08:52
11245
Pictor and Disease Research Limited Formalise Collaboration to Advance Johne's Disease Monitoring Across New Zealand
Building on a two-year scientific collaboration and co-authored peer-reviewed publication, the collaboration supports new approaches to herd health monitoring for New Zealand's dairy and beef sectors AUCKLAND, New Zealand, May 20, 2026 /PRNewswire/ -- Pictor, a global targeted proteomics platfor...
2026-05-20 20:56
3757
Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Study now open for enrollment at leading academic medical centers CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-hu...
2026-05-20 20:00
5986
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from Japan's biopharmaceutical industry, exchanging the ...
2026-05-20 13:44
9031
Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research
Collaboration expands research of new delivery platform beyond liver tissues
supporting potential preclinical development and strengthens Singapore's
position as a biomedical innovation hub
SINGAPORE, May 20, 2026 /PRNewswire/ -- Agilent Technologies Inc.
2026-05-20 11:00
6250
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-05-20 08:00
6485
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
* IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. * Maximum dose reached with no dose-limiting toxicities observed. * TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma. MELBOURNE, Australia ...
2026-05-19 05:00
8595
Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing
NORWALK, Conn., May 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC...
2026-05-19 01:03
5629
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
19342
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12324
MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market
2026-09-26 08:55
9598
